Press release centre
Past Press Releases - Cytheris SA
October 24, 2012 Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of PML Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of Progressive Multifocal Leucoencephalopathy (PML). More
July 10, 2012 Cytheris announces CYT107 orphan drug designation in Europe for the treatment of PML Cytheris announces CYT107 orphan drug designation in Europe for the treatment of Progressive Multifocal Leucoencephalopathy (PML). More
February 22, 2011 Cytheris announces publication of preclinical study in Cell ... Cytheris announces publication of preclinical study in Cell showing that interleukin-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. More
December 7, 2010 Cytheris announces interim results of Phase I study showing that recombinant human interleukin-7 ... Cytheris announces interim results of Phase I study showing that recombinant human interleukin-7 (CYT107) promotes T-cell recovery following T-cell depleted allogeneic hematopoietic stem cell transplantation. More
October 19, 2010 Cytheris announces initiation of ORVACS-sponsored phase II clinical study Cytheris announces initiation of ORVACS-sponsored phase II clinical study combining immunomodulatory intervention with Interleukin-7 (CYT107) and antiretroviral intensification with raltegravir and maraviroc to attack the viral reservoir of HIV patients More
March 16, 2010 Cytheris announces publication of preclinical study in Journal of Immunology ... Cytheris announces publication of preclinical study in Journal of Immunology showing Interleukin-7 promotes T cell viability, trafficking and functionality while improving survival in sepsis. More
February 2, 2010 Cytheris announces notice of allowance for U.S. patent covering the preparation and uses of CYT107 Cytheris announces notice of allowance for U.S. patent covering the preparation and uses of its glycosylated recombinant human interleukin-7 (CYT107) More
December 8, 2009 Cytheris announces initiation of CONVERT, a Phase I/IIa study ... Cytheris announces initiation of CONVERT, a Phase I/IIa study of recombinant human Interleukin-7 (CYT107) in combination with antiviral therapy and vaccination for treatment of chronic hepatitis B virus. More
November 23, 2009 Cytheris announces initiation of NCI/NIH-sponsored phase I/IIa clinical study Cytheris announces initiation of NCI/NIH-sponsored phase I/IIa clinical study of tumor vaccination and interleukin-7 (IL-7) in patients with high risk pediatric solid tumors. More
October 14, 2009 Cytheris announces initiation of NIAID/NIH-sponsored Phase I/IIa clinical trial of interleukin-7 Study to focus on immunotherapy for treatment of idiopathic CD4 lymphocytopenia (ICL), a rare condition for which no treatment currently exists More
October 28, 2008 Cytheris initiates Asian Phase I/IIa clinical trial of Interleukin-7 (IL-7) as an immunotherapy ... Taiwan trial studies patients who failed to achieve SVR with standard treatment, and complements Company's two other investigations in naïve and previously non-responsive HCV patients currently ongoing in Europe More
July 15, 2008 Cytheris receives EUR 1.5 million (USD 2.3 million) from OSEO for HCV clinical development program Highly competitive government award for Paris region recognizes potential of Interleukin-7 as an immunotherapy More
June 26, 2008 Cytheris announces publication of IL-7 oncology data in The Journal of Experimental Medicine Results of a second phase 1 trial in oncology further demonstrate the potential of Interleukin-7 to induce dramatic and prolonged CD4 and CD8 T cell expansion More
April 23, 2008 Cytheris announces new phase I study of Interleukin-7 as immunotherapy Cytheris announces new phase I study of Interleukin-7 as immunotherapy in treatment of bone barrow or peripheral blood stem cell transplant patients More
November 26, 2007 Cytheris appoints Richard Keatinge as Chief Business Officer Company further strengthens management team with experienced international biotech business executive More
September 26, 2007 Cytheris expands Interleukin-7 clinical development program with phase I/IIa trial in HIV Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced expansion of the clinical trial program for CYT107, the company's recombinant human Interleukin-7 (IL-7), with the initiation of a Phase I/IIa clinical trial in HIV patients. More |